** AbbVie ABBV.N raised its full-year profit forecast on Friday while downplaying the potential hit some analysts expect it to take from sector-specific import duties that could be imposed by the Trump administration

** Average recommendation of 28 brokerages is "buy", median PT is $210 - data compiled by LSEG

PLAYING WITH A STRONG PIPELINE

** J.P.Morgan ("overweight") sees growth potential from newer immunology drugs Skyrizi and Rinvoq, and ABBV has the financial capacity for further business development into the 2030s

** "We see ABBV with slightly above average exposure to potential tariffs, given the company's more US-centric sales mix" - JPM

** BofA Global Research ("neutral," PO: $200) says ABBV's strength lies in having fewer patent expirations this decade, and continues to observe that consensus under model Skyrizi and Rinvoq, which could be a source of growth

** Citigroup ("buy," PT: $210) says co's strong U.S. presence could help mitigate potential near-term pharma tariffs better than expected

** Leerink Partners ("outperform", PT: $210) says "Skyrizi's U.S. supply is sourced from domestic manufacturing, and AbbVie's broad global manufacturing footprint could help mitigate the impact of tariffs"

(Reporting by Akriti Shah in Bengaluru)

((akriti.shah@thomsonreuters.com))